Skip to main content

Table 4 Overview of studies evaluating different nCRT regimes for EC

From: Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus

Author (year)

N° of patients

Study design

Histology

RTx

CTx regime

Median OS in months

Local failure rate

pCR rate

Hemato-logic toxicity (≥ III°)

Bates [8] (1996)

35

Phase 2

80% SCC

45 Gy (25 Fx)

Cisplatin 5FU

25.8

7%

51%

17%

Tepper [2] (2008)

30 (trimodal therapy)

Phase 3

23% SCC

50.4 Gy (28 Fx)

Cisplatin 5FU

53.8

13%

40%

57%

Bosset [18] (1997)

143 (trimodal therapy)

Phase 3

100% SCC

18.5 Gy (5 Fx)

Cisplatin (0–2 days before first day of radiotherapy)

18.6

26%

van Hagen; Shapiro [3, 10] (2012; 2015)

178 (trimodal therapy)

Phase 3

23% SCC

41.4 Gy (23 Fx)

Carboplatin Paclitaxel

48.6 (all)

81.6 (SCC)

22%

29% (all)

49% (SCC)

8%

Bedenne [11] (2007)

129 (trimodal therapy)

Phase 3

89% SCC

46 Gy (23 Fx) or 15 Gy (5 Fx) – week 1 + 4

Cisplatin 5-Fluoruracil

17.7

33.6%

Urba [19] (2003)

69

Phase 2

14% SCC

45 Gy (30 Fx) – twice daily

Cisplatin Paclitaxel

24

22%

13%a

Blom [4] (2014)

165

Retro-spective analysis

24% SCC

1. 50.4 Gy (28 Fx)

2. 41.4 Gy (23 Fx)

1. Cisplatin 5-Fluoruracil

2. Carboplatin Paclitaxel

Not reached after 3 years

38%

24%

1.15%a

2.2% a

van Meerten [14] (2006)

54

Phase 2

22% SCC

41.4 Gy (23 Fx)

Carboplatin Pacliataxel

Not reached after median follow up of 31 months

13%

25%

25% a

This analysis

51

Retro-spective analysis

100% SCC

1. 45 Gy (25 Fx)

2. 41.4 Gy (23 Fx)

1. Cisplatin 5-Fluoruracil

2. Carboplatin Paclitaxel

1. 40.1

2. 23.9

1. 34%

2. 21%

1. 38%

2. 26%

1. 58%

2. 20%

  1. a neutropenia, RTx radiotherapy, CTx chemotherapy, SCC squamous cell carcinoma, Fx fractions